Innovent, ASK Pharm’s lung cancer drug limertinib approved in China
China’s NMPA approved Innovent and ASK Pharm’s New Drug Application (NDA) for limertinib to treat adults with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC)
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry